Dr. Hoos on Tools Available to Measure Ipilimumab's Success

Axel Hoos, MD, PhD
Published: Thursday, Jul 07, 2011

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb describes the tools currently available and peer reviewed for the measurement of ipilimumab's success. These studies all need to be validated prospectively in comparison to standard processes.
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb describes the tools currently available and peer reviewed for the measurement of ipilimumab's success. These studies all need to be validated prospectively in comparison to standard processes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x